Abstract
The combination of COVID-19 vaccination with immunotherapy by checkpoint inhibitors in cancer patients could intensify immunological stimulation with potential reciprocal benefits. Here, we examine more closely the possible adverse events that can arise in each treatment modality. Our conclusion is that caution should be exercised when combining both treatments.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
BNT162 Vaccine / administration & dosage
-
BNT162 Vaccine / adverse effects*
-
BNT162 Vaccine / immunology
-
COVID-19 / immunology
-
COVID-19 / prevention & control*
-
COVID-19 Vaccines / administration & dosage
-
COVID-19 Vaccines / adverse effects
-
COVID-19 Vaccines / immunology
-
Combined Modality Therapy / adverse effects
-
Cytokine Release Syndrome / etiology
-
Drug Interactions
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immune Checkpoint Inhibitors / adverse effects*
-
Immunotherapy / adverse effects*
-
Immunotherapy / methods
-
Neoplasms / immunology
-
Neoplasms / therapy*
Substances
-
COVID-19 Vaccines
-
Immune Checkpoint Inhibitors
-
BNT162 Vaccine